SCHEMBL13264604

SCHEMBL13264604

COC(=O)Cc1cnc(Cc2ccc(N=O)cc2)nc1C

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 8/20 0.36
MBOAT4 Q96T53 1/20 0.36
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
ALDH1A1 P00352 2/20 0.34
EGFR P00533 1/20 0.34
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
EGLN1 Q9GZT9 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
CNR2 P34972 1/20 0.33
PRNP P04156 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13264545 0.88 EGFR (0.37) TLR7MBOAT4NPC1RAB9AALDH1A1
SCHEMBL13264579 0.88 ALDH1A1 (0.39) TLR7MBOAT4NPC1RAB9AALDH1A1
SCHEMBL13264603 0.81 TLR7 (0.33) TLR7MBOAT4NPC1RAB9AALDH1A1
SCHEMBL13264548 0.78 TLR7 (0.40) TLR7MBOAT4NPC1RAB9AALDH1A1
SCHEMBL13446380 0.74 NPSR1 (0.41) TLR7NPC1RAB9AALDH1A1CYP4F2
SCHEMBL12112942 0.73 CYP4F2 (0.59) NPC1RAB9AALDH1A1CYP4F2CYP4A11
SCHEMBL13818337 0.73 EGLN1 (0.36) EGLN1KDM4E
SCHEMBL13264602 0.72 EGFR (0.34) NPC1RAB9AALDH1A1EGFRCYP4F2
SCHEMBL12568854 0.71 ALDH1A1 (0.36) TLR7MBOAT4NPC1RAB9AALDH1A1
SCHEMBL13236237 0.70 PTGS2 (0.43) ALDH1A1SMN1; SMN2GAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750014-B2 Imidazo[1,2-C]pyrimidinylacetic acid derivatives ACTIMIS PHARMACEUTICALS, INC. (US) 2010-07-06 US disclosed
US-20090012102-A1 Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives ACTIMIS PHARMACEUTICALS, INC. (US) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012102-A1 Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives HRH2, CCR2, HRH1 TLR7 304/4885MBOAT4 4738/4885NPC1 2986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.